Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy

NCT04440358 is registered in ClinicalTrials.gov with InSightec as lead sponsor.

NCT NCT04440358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04440358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Lead sponsor
InSightec
Phase
Phase 1/2
Overall status
Completed
Start date
October 13, 2020
Completion date
December 31, 2023
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma